BlackRock, Inc. 13D and 13G filings for Inozyme Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-17 7:54 pm Sale | 2025-06-30 | 13G | INOZYME PHARMA INC INZY | BlackRock Inc. BLK | 2,663,678 4.100% | -827,558 (-23.70%) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | INOZYME PHARMA INC INZY | BlackRock Inc. BLK | 3,491,236 5.600% | 0 (Unchanged) | Filing |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | INOZYME PHARMA INC INZY | BlackRock Inc. BLK | 3,491,236 5.600% | 3,491,236 (New Position) | Filing |